TRANSCODE THERAPEUTICS, INC.

RNA Interference - (RNAi)

RNAi has emerged as a powerful tool for therapeutic gene silencing....Its potential for therapy is indisputable, considering that one can use this mechanism to silence genes implicated in carcinogenesis and metastasis.

Transforming cancer treatment

TransCode Therapeutics, Inc., an RNAi Oncology Company, is focused on the discovery, development and commercialization of a pipeline of innovative diagnostics and therapeutics for the detection and treatment of cancer, with an initial focus on metastasis. TransCode’s vision is to be the leader in RNAi in Oncology employing data-driven cancer diagnostics as well as optimized targeted treatment solutions for each individual cancer patient that results in a significant improvement in their outcome.

Individualized Patient Approach

STRATEGIC DRIVERS

Improve Cancer Outcomes
Initial Focus on Metastasis
Image-guided Therapeutic Delivery
Data Driven - Translational Bioinformatics
Early Detection of Disease

Conventional therapies aimed at treating primary cancer oftentimes are ineffective at treating metastatic cancer, resulting in poor outcomes in patients diagnosed with metastatic disease.

Improve Cancer Outcomes

A need for differential treatment is paramount
Initial Focus on Metastasis
Initial goal is to significantly improve treatment outcomes in patients with late stage disease
Individual patient treatments based on mutation type, stage of disease and biomarker expression
Optimize dose and treatment duration for each individual patient

Image-guided Delivery Platform

Image-guided treatment combines knowledge of drug bioavailability & outcome
Delivery-based therapeutic platform - backbone of therapeutic pipeline
Therapeutics targeting specific biomarkers in multiple cancer types
Combination therapies as a multipronged approach to treatment

Data Driven

Identify key biomarkers associated with primary and metastatic cancers
Apply highly specific biomarker diagnostic tools for cancer detection and staging
Assimilate biomarker expression data, stage of disease, tumor type, aggressiveness of disease
Translational bioinformatics - data to inform therapeutic decision making and early intervention

Early Detection

The staple of reducing mortality due to cancer has been early detection.

Utilize novel diagnostic biomarkers for the presence of metastasis
Develop predictive biomarkers for early diagnosis of metastasis and disease progression
Identify patients at increased risk of progression
Stratify tumors based on aggressiveness to better inform treatment